Expert Matthew D. Galsky, MD, shares his perspective on follow-up results from CheckMate 274, which analyzed adjuvant nivolumab in patients with high-risk muscle-invasive urothelial carcinoma.
Grivas Spotlights Advances With Immunotherapy-Based Approaches in Urothelial Cancer
Revisit the OncLive On Air Episodes From February 2024
Salvage Nivolumab/Ipilimumab Following Nivolumab Affords Treatment-Free Survival in RCC
FDA Approval Insights: Enfortumab Vedotin Plus Pembrolizumab in Urothelial Carcinoma
EV-302 Trial Ushers in Era of Novel Combos in First-Line Metastatic Urothelial Cancer
Time to Bladder Cancer Treatment Is Similar Among Black and White Patients, But Other Disparities Persist
Dr Jia on the Evolving Role of Metastasis-Directed Radiotherapy in Prostate Cancer
Dr Wang on the Limited Utility of Quantitative Molecular Imaging Thresholds in RCC
Darolutamide Use Is Routine in Both Doublets and Triplet Therapies in mHSPC